Xeris Biopharma Holdings, Inc. XERS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $314.85M+41.5% | $291.85M+43.7% | $266.14M+42.0% | $246.03M+35.6% | $222.55M+29.9% | ||
| $44.42M+12.2% | $42.57M+15.6% | $41.1M+17.7% | $43.7M+48.0% | $39.59M+35.1% | ||
| $32.2M+26.3% | $31.17M+21.9% | $29.38M+13.7% | $27.79M+11.2% | $25.49M+0.7% | ||
| $191.5M+13.2% | $182.37M+11.6% | $175.01M+8.8% | $173.52M+13.2% | $169.12M+12.1% | ||
| $278.95M+13.8% | $266.95M+12.8% | $256.34M+10.2% | $255.85M+17.0% | $245.04M+13.3% | ||
| $35.9M+249% | $24.9M+170% | $8.12M+118% | -$11.5M+69.1% | -$24.17M+46.3% | ||
| 11.4%+22.3pp | 8.5%+25.9pp | 3.1%+27.2pp | -4.7%+15.8pp | -10.9%+15.4pp | ||
| $28.66M-6.8% | $29.08M-4.6% | $29.63M-0.6% | $30.15M+4.5% | $30.76M+12.2% | ||
| -$23.89M+5.0% | -$24.34M-3.8% | -$25.44M-24.4% | -$25.5M-16.5% | -$25.16M-23.5% | ||
| $0+100% | $0+100% | $0+100% | -$3.32M-790% | -$2.58M-173% | ||
| $12.01M+127% | $554K+101% | -$15.64M+75.2% | -$32M+46.3% | -$45.08M+30.0% | ||
| 3.8%+24.1pp | 0.2%+27.2pp | -5.9%+27.8pp | -13%+19.8pp | -20.3%+17.3pp | ||
| $0.07+123% | $0.00+100% | -$0.10+77.3% | -$0.21+50.0% | -$0.30+34.8% | ||
| $37.24M+262% | $26.21M+177% | $9.41M+121% | -$10.24M+71.4% | -$22.95M+47.3% | ||
| 11.8%+22.1pp | 9%+25.8pp | 3.5%+27.0pp | -4.2%+15.6pp | -10.3%+15.1pp | ||
| $35.9M+249% | $24.9M+170% | $8.12M+118% | -$11.5M+69.1% | -$24.17M+46.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s revenue?
- Xeris Biopharma Holdings, Inc. (XERS) generated $314.9M in revenue over the trailing twelve months, up 41.5% year over year.
- Is Xeris Biopharma Holdings, Inc. profitable?
- Xeris Biopharma Holdings, Inc. reported $12.0M in net income over the trailing twelve months, a 3.8% net margin.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Gross margin is 85.9% and operating margin is 11.4%, with a 3.8% net margin.
- What is Xeris Biopharma Holdings, Inc.'s earnings per share?
- Xeris Biopharma Holdings, Inc.'s diluted EPS over the trailing twelve months is $0.07.
- Where does Xeris Biopharma Holdings, Inc.'s income statement data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
